BioSpace News Archive

AstraZeneca and Merck announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].

Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.

Corindus Vascular Robotics, Inc. today announced that it will release financial and business results for the second quarter of 2018 after the close of trading on Tuesday, August 7, 2018.

Lannett Company, Inc. announced that it has entered into an exclusive perpetual licensing agreement with Andor Pharmaceuticals, LLC for Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths.

ZHilado and Jafry Bring Financial Acumen and Global Experience to Board of Directors

Funding Round Will Bolster Fitness Company’s International Expansion, Product Innovation and Retail Footprint

Bob Moran Becomes Lead Independent Director

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into an amendment (the “Amendment”) of the previously announced definitive asset purchase, supply and support agreement (the “Purchase Agreement”) with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®.

Omeros Corporation announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes.